Skye Bioscience Statistics
Total Valuation
Skye Bioscience has a market cap or net worth of $4.38 million. The enterprise value is -$5.50 million.
| Market Cap | 4.38M |
| Enterprise Value | -5.50M |
Important Dates
The next estimated earnings date is Friday, November 20, 2026, after market close.
| Earnings Date | Nov 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Skye Bioscience has 4.43 million shares outstanding. The number of shares has increased by 0.08% in one year.
| Current Share Class | 4.43M |
| Shares Outstanding | 4.43M |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 1.16% |
| Owned by Institutions (%) | 17.77% |
| Float | 3.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.95
| Current Ratio | 0.95 |
| Quick Ratio | 0.87 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8,740.65 |
Financial Efficiency
Return on equity (ROE) is -233.87% and return on invested capital (ROIC) is -137.38%.
| Return on Equity (ROE) | -233.87% |
| Return on Assets (ROA) | -95.06% |
| Return on Invested Capital (ROIC) | -137.38% |
| Return on Capital Employed (ROCE) | 9,663.26% |
| Weighted Average Cost of Capital (WACC) | 20.83% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$25.25M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Skye Bioscience has paid $3,400 in taxes.
| Income Tax | 3,400 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.80% in the last 52 weeks. The beta is 3.15, so Skye Bioscience's price volatility has been higher than the market average.
| Beta (5Y) | 3.15 |
| 52-Week Price Change | -91.80% |
| 50-Day Moving Average | 1.64 |
| 200-Day Moving Average | 4.69 |
| Relative Strength Index (RSI) | 24.16 |
| Average Volume (20 Days) | 24,542 |
Short Selling Information
The latest short interest is 140,313, so 3.17% of the outstanding shares have been sold short.
| Short Interest | 140,313 |
| Short Previous Month | 147,954 |
| Short % of Shares Out | 3.17% |
| Short % of Float | 4.46% |
| Short Ratio (days to cover) | 2.47 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -48.06M |
| Pretax Income | -50.49M |
| Net Income | -50.49M |
| EBITDA | -47.37M |
| EBIT | -48.06M |
| Earnings Per Share (EPS) | -$10.24 |
Balance Sheet
The company has $10.06 million in cash and $178,746 in debt, with a net cash position of $9.89 million or $2.23 per share.
| Cash & Cash Equivalents | 10.06M |
| Total Debt | 178,746 |
| Net Cash | 9.89M |
| Net Cash Per Share | $2.23 |
| Equity (Book Value) | -497,307 |
| Book Value Per Share | -0.11 |
| Working Capital | -572,215 |
Cash Flow
| Operating Cash Flow | -38.81M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 689,391 |
| Net Borrowing | -178,813 |
| Free Cash Flow | -38.81M |
| FCF Per Share | -$8.77 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Skye Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.08% |
| Shareholder Yield | -0.08% |
| Earnings Yield | -1,034.02% |
| FCF Yield | -885.13% |
Analyst Forecast
The average price target for Skye Bioscience is $68.00, which is 6,766.61% higher than the current price. The consensus rating is "Buy".
| Price Target | $68.00 |
| Price Target Difference | 6,766.61% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on August 24, 2026. It was a reverse split with a ratio of 1:8.
| Last Split Date | Aug 24, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |